HIV-1 seropositive subjects under HAART treatment used for ‘Opal-HIV-Gag(c)’ vaccine administration.

Abstract

a<p>Values obtained at baseline defined as day of first vaccination.</p>b<p>Withdrawn from study after two administrations (014) or after one administration (019 and 024).</p